ly3437943 retatrutide triple agonist glp-1 gip glucagon LY3437943, a novel glucagon, GIP, and receptor for glycemic control and weight loss: From discovery to clinical proof of concept Frontiers | Glucagon-like peptide-1 and
Description
They are central to how patients experience GLP-1 therapy and how successfully they remain on treatment
In the over 2500 participants, who were assigned to the 5, 10, and 15 mg doses of tirzepatide and placebo, the percent weight changes were both statistically and clinically significant compared with placebo
While prior literature cites a 510% defect rate among women with pregestational diabetes, this study did not report any significant pregnancy losses following the use of GLP-1RA (92)
The right choice depends on your individual situation
